KUALA LUMPUR, 13 October 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code:9601) is pleased to announce that the nucleic acid test kits manufactured by Wuhan Easydiagnosis Biomedicine Co Ltd (“Wuhan Easydiagnosis”) and authorised for distribution in Malaysia has passed with 100% accuracy an evaluation by the Ministry of Health’s (“MOH”) National Public Health Laboratory (“NPHL”).
The analysis results by the NPHL showed that the test kit, known as the eDiagnosis COVID-19 nucleic acid test kit, passed the sensitivity and specificity tests for the 30 samples that were found to be COVID-19 positive and the 30 samples that were COVID-19 negative.
The evaluation of the test kit was carried out on ribonucleic acid (“RNA”) material extracted from nasopharyngeal and oropharyngeal swabs from positive cases and non-COVID-19 patients. RNA is the nucleic acid present in all living cells.
General Manager, Medical & Pharmaceutical Research of HWGB Biotech, Dr. Yaman Walid Kassab said: “The results from the MOH evaluation shows that the test kits we are distributing is highly reliable as it passed with 100% accuracy”.
“The next step for us is to submit the test kit for Medical Device Authority (“MDA”) approval and when it is approved, we can market and distribute the test kits. We hope that having this test kit in the market will help to reduce the spread of COVID-19 more effectively”. MDA is a statutory agency within the MOH entrusted with addressing public health and safety issues related to medical devices and to facilitate medical device trade and industry.
Wuhan Easydiagnosis had authorised HWGB Biotech Sdn Bhd (“HWGB Biotech”) (fka HWG Consortium Sdn Bhd), a wholly-owned subsidiary of HWGB, in March this year to distribute the test kits in Malaysia. Shanghai Liangrun Biomedicine Technology Co Ltd and Sansure Biotech Inc have also authorised the Company to be distributors of their test kits in May and June respectively.
ABOUT HO WAH GENTING BERHAD
Ho Wah Genting Berhad (“HWGB” or the “Company”) is
principally engaged in investment holdings and the provision of management services
to its subsidiaries. The Company had on 30 June 2020 diversified its existing
businesses to include healthcare related industry which mainly involved in Health
Supplement, Biotechnology and Health Technology. In addition, the Company and
its subsidiaries (“HWGB Group” or the “Group”) are also engaging in
the businesses of Investment holdings; manufacturing of wires and cables and
moulded power supply cord sets and cable assemblies for electrical and
electronic devices and equipment; Trading of wires and cables; and travel agent
and tour related services.
Walid Kassab is an assistant Professor of Clinical Pharmacy. He
obtained his PhD in Clinical Pharmacy at University Science Malaysia (USM) in
2013. He possesses 7 years of experience in the academia, specifically in the
pharmacotherapy field. He is actively involved in medical research and
publication and has published more than 40SCOPUS/ISI indexed research papers
and has supervised more than 50 research projects and 20 postgraduate research
students. He is also serving as an editorial Board member of several reputed international
journals like “Frontiers in Pharmacology”, “Archives of Pharmacy Practice
(APP)” , “Journal of Medical and Pharmaceutical Innovation (JMPI)” , ”Annals of
Cardiology and Cardiovascular Diseases” , “Updates in Public Health and
Preventive Medicine” He has been a member of many international professional
bodies such as International Association of Therapeutic Drug Monitoring &
Clinical Toxicology in CANADA, Syndicate of Syrian Pharmacists, Malaysian
Association of Education in Medicine & Health Sciences, Malaysian
Biomedicine Co Ltd (SHE: 002932)
Wuhan Easy Diagnosis Biomedicine Co., Ltd, Located in the National
Biological Industry Base in Wuhan province, China. The Company is a leading IVD
manufacturer, specializing in development, production and sales of POCT rapid
diagnostic reagents and related equipment.
Equipped with a strong and professional R&D team, with 100,000 grade
clean workshop and international leading production lines. All of the company
products line has gotten ISO13485：2016, CE
certification, and more than 30 parameters of POCT rapid diagnostic products
with SFDA registration. Also, the Company is the first company making bedside,
rapid and quantitative detection in whole blood in China and their products are
selling in more than 20 countries. The Company intelligent management system
provides hospital departments at all levels detections including cardiovascular
disease, kidney disease, infectious disease, endocrine and metabolic diseases,
obstetrics and gynecology, and eugenics, physical examination and other